LAMOTRIGINE
HIV Infection
Radboud University Medical CenterSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
62 Active assets in the HIV Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raltegravir Helsinki University Central Hospital | Phase 4 | A |
ZIDOVUDINE International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Phase 4 | BBB |
Efavirenz The Cleveland Clinic | Phase 4 | BBB |
Ganciclovir | Phase 4 | BBB |
RITONAVIR Giovanni Di Perri | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
LAMOTRIGINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →